TY  - JOUR
A1  - Lückerath, Katharina
A1  - Lapa, Constantin
A1  - Albert, Christa
A1  - Herrmann, Ken
A1  - Jörg, Gerhard
A1  - Samnick, Samuel
A1  - Einsele, Herrmann
A1  - Knop, Stefan
A1  - Buck, Andreas K.
T1  - \(^{11}\)C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma
JF  - Oncotarget
N2  - Multiple myeloma (MM) remains an essentially incurable hematologic malignancy. However, new treatment modalities and novel drugs have been introduced and thus additional tools for therapy monitoring are increasingly needed. Therefore, we evaluated the radiotracers \(^{11}\)C-Methionine (paraprotein-biosynthesis) and \(^{18}\)F-FDG (glucose-utilization) for monitoring response to anti-myeloma-therapy and outcome prediction. Influence of proteasome-inhibition on radiotracer-uptake of different MM cell-lines and patient-derived CD138\(^{+}\) plasma cells was analyzed and related to tumor-biology. Mice xenotransplanted with MM. 1S tumors underwent MET- and FDG-\(\mu\)PET. Tumor-to-background ratios before and after 24 h, 8 and 15 days treatment with bortezomib were correlated to survival. Treatment reduced both MET and FDG uptake; changes in tracer-retention correlated with a switch from high to low CD138-expression. In xenotransplanted mice, MET-uptake significantly decreased by 30-79% as early as 24 h after bortezomib injection. No significant differences were detected thus early with FDG. This finding was confirmed in patient-derived MM cells. Importantly, early reduction of MET-but not FDG-uptake correlated with improved survival and reduced tumor burden in mice. Our results suggest that MET is superior to FDG in very early assessment of response to anti-myeloma-therapy. Early changes in MET-uptake have predictive potential regarding response and survival. MET-PET holds promise to individualize therapies in MM in future.
KW  - positron emission tomography
KW  - imaging techniques
KW  - experience
KW  - \(^{11}\)C-Methionine-PET
KW  - treatment response
KW  - molecular imaging
KW  - multiple myeloma
KW  - management
KW  - \(^{18}\)F-FDG PET/CT
KW  - bone disease
KW  - stem-cell transplantation
KW  - esophagogastric junction
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148688
VL  - 6
IS  - 10
ER  - 
TY  - JOUR
A1  - Kirscher, Lorenz
A1  - Deán-Ben, Xosé Luis
A1  - Scadeng, Miriam
A1  - Zaremba, Angelika
A1  - Zhang, Qian
A1  - Kober, Christina
A1  - Fehm, Thomas Felix
A1  - Razansky, Daniel
A1  - Ntziachristos, Vasilis
A1  - Stritzker, Jochen
A1  - Szalay, Aladar A.
T1  - Doxycycline Inducible Melanogenic Vaccinia Virus as Theranostic Anti-Cancer Agent
JF  - Theranostics
N2  - We reported earlier the diagnostic potential of a melanogenic vaccinia virus based system in magnetic resonance (MRI) and optoacoustic deep tissue imaging (MSOT). Since melanin overproduction lead to attenuated virus replication, we constructed a novel recombinant vaccinia virus strain (rVACV), GLV-1h462, which expressed the key enzyme of melanogenesis (tyrosinase) under the control of an inducible promoter-system. In this study melanin production was detected after exogenous addition of doxycycline in two different tumor xenograft mouse models. Furthermore, it was confirmed that this novel vaccinia virus strain still facilitated signal enhancement as detected by MRI and optoacoustic tomography. At the same time we demonstrated an enhanced oncolytic potential compared to the constitutively melanin synthesizing rVACV system.
KW  - reporter gene
KW  - oncolysis
KW  - molecular imaging
KW  - virotherapy
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124987
VL  - 5
IS  - 10
ER  -